Cancer cure for 32 cancer types: results from the EUROCARE-5 study - Lipides Nutrition Cancer - UMR866 Accéder directement au contenu
Article Dans Une Revue International Journal of Epidemiology Année : 2020

Cancer cure for 32 cancer types: results from the EUROCARE-5 study

Riccardo Capocaccia
  • Fonction : Auteur
Tadek Dyba
  • Fonction : Auteur
Silvia Franceschi
Anna Gigli
  • Fonction : Auteur
Francesco Giusti
  • Fonction : Auteur
Valerie Jooste
  • Fonction : Auteur
Pamela Minicozzi
  • Fonction : Auteur
Luciana Neamtiu
  • Fonction : Auteur
Roberta de Angelis
  • Fonction : Auteur

Résumé

Background : Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. Methods : 7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15–74 years in 1990–2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%. Results : LEF ranged from 10 years for chronic lymphocytic leukaemia patients to <6 months for those with liver, pancreas, brain, gallbladder and lung cancers. It was 7.7 years for patients with prostate cancer at age 65–74 years and >5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and <10% for liver, lung and pancreatic cancers. TTC was <5 years for testis and thyroid cancer patients diagnosed below age 55 years, and <10 years for stomach, colorectal, corpus uteri and melanoma patients of all ages. For breast and prostate cancers, a small excess (CRS < 95%) remained for at least 15 years. Conclusions : Estimates from this analysis should help to reduce unneeded medicalization and costs. They represent an opportunity to improve patients’ quality of life.

Dates et versions

hal-03088676 , version 1 (26-12-2020)

Identifiants

Citer

Luigino Dal Maso, Chiara Panato, Andrea Tavilla, Stefano Guzzinati, Diego Serraino, et al.. Cancer cure for 32 cancer types: results from the EUROCARE-5 study. International Journal of Epidemiology, 2020, 49 (5), pp.1517-1525. ⟨10.1093/ije/dyaa128⟩. ⟨hal-03088676⟩
86 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More